Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TC2N

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Malignant tumor immunotherapy relies on identifying cytotoxic T lymphocyte (CTL) epitopes from tumor-associated antigens.
• TC2N, a recently identified human glioblastoma antigen, presents a potential target for tumor-specific immunotherapy.
• HLA-A*0201 is a common histocompatibility molecule, making it a relevant target for immunotherapeutic strategies in specific populations.

Purpose of the Study:

• To identify and characterize HLA-A*0201-restricted CTL epitopes derived from the TC2N tumor antigen.
• To evaluate the immunotherapeutic potential of identified TC2N-derived peptides against glioblastoma.

Main Methods:

• Bioinformatic prediction of antigenic peptides from TC2N.
• Synthesis and binding affinity evaluation of top-scoring peptides with HLA-A*0201.
• In vitro and in vivo stimulation of T-cell responses against predicted peptides.
• Assessment of IFN-γ release and tumor cell lysis mediated by elicited CTLs.

Main Results:

• The peptide TC2N (152-160), with sequence RLYGSVCDL, demonstrated significant binding affinity to HLA-A*0201.
• In vitro and in vivo studies confirmed that TC2N (152-160) elicits peptide-specific CTLs.
• These CTLs were capable of releasing IFN-γ and lysing U251 glioblastoma cells.

Conclusions:

• Peptide TC2N (152-160) (RLYGSVCDL) is a novel HLA-A2.1-restricted CTL epitope.
• This epitope can induce TC2N-specific CTLs, demonstrating its potential for glioblastoma immunotherapy.
• The identified epitope RLYGSVCDL may be a valuable component for developing peptide-based, cancer-specific immunotherapies for GBM.